Deciphering the association between HIV-specific immunity and immune reconstitution

by Ole S. Søgaard
Published 2021-05-01

TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure

by Caroline Thue Hvilsom, Ole Schmeltz Søgaard, Ole Schmeltz Søgaard
Published 2021-09-01

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues

by Paul W. Denton, Ole S. Søgaard, Ole S. Søgaard, Martin Tolstrup, Martin Tolstrup
Published 2019-08-01

Polysaccharide responsiveness is not biased by prior pneumococcal-conjugate vaccination.

by Jens Magnus Bernth-Jensen, Ole Schmeltz Søgaard
Published 2013-01-01

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies

by Janne Tegder Martinsen, Jesper Damsgaard Gunst, Jesper Falkesgaard Højen, Martin Tolstrup, Ole Schmeltz Søgaard
Published 2020-06-01

Immune checkpoints and the HIV-1 reservoir: proceed with caution

by Rikke Olesen, Steffen Leth, Rasmus Nymann, Lars Østergaard, Ole S. Søgaard, Paul W. Denton, Martin Tolstrup
Published 2016-07-01

Morbidity and risk of subsequent diagnosis of HIV: a population based case control study identifying indicator diseases for HIV infection.

by Ole S Søgaard, Nicolai Lohse, Lars Østergaard, Gitte Kronborg, Birgit Røge, Jan Gerstoft, Henrik T Sørensen, Niels Obel
Published 2012-01-01

The impact of B-cell perturbations on pneumococcal conjugate vaccine response in HIV-infected adults.

by Thomas G Johannesson, Ole S Søgaard, Martin Tolstrup, Mikkel S Petersen, Jens M Bernth-Jensen, Lars Østergaard, Christian Erikstrup
Published 2012-01-01

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation

by Jesper D. Gunst, Kathrine Kjær, Rikke Olesen, Thomas A. Rasmussen, Lars Østergaard, Paul W. Denton, Ole S. Søgaard, Martin Tolstrup
Published 2019-07-01

Risk and Prognosis of Bloodstream Infections among Patients on Chronic Hemodialysis: A Population-Based Cohort Study.

by Lars Skov Dalgaard, Mette Nørgaard, Bente Jespersen, Søren Jensen-Fangel, Lars Jørgen Østergaard, Henrik Carl Schønheyder, Ole Schmeltz Søgaard
Published 2015-01-01

Mortality after hospitalization for pneumonia among individuals with HIV, 1995-2008: a Danish cohort study.

by Ole S Søgaard, Nicolai Lohse, Jan Gerstoft, Gitte Kronborg, Lars Østergaard, Court Pedersen, Gitte Pedersen, Henrik Toft Sørensen, Niels Obel
Published 2009-01-01

Endotoxemia is associated with altered innate and adaptive immune responses in untreated HIV-1 infected individuals.

by Anne Roslev Bukh, Jesper Melchjorsen, Rasmus Offersen, Jens Magnus Bernth Jensen, Lars Toft, Henrik Støvring, Lars Ostergaard, Martin Tolstrup, Ole Schmeltz Søgaard
Published 2011-01-01

Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients.

by Anni A Winckelmann, Lærke V Munk-Petersen, Thomas A Rasmussen, Jesper Melchjorsen, Thomas J Hjelholt, David Montefiori, Lars Østergaard, Ole S Søgaard, Martin Tolstrup
Published 2013-01-01

Comparable human reconstitution following Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice.

by Anna Halling Folkmar Andersen, Stine Sofie Frank Nielsen, Rikke Olesen, Jakob Le Fèvre Harslund, Ole Schmeltz Søgaard, Lars Østergaard, Paul W Denton, Martin Tolstrup
Published 2020-01-01

Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days.

by Mykola Pinkevych, Stephen J Kent, Martin Tolstrup, Sharon R Lewin, David A Cooper, Ole S Søgaard, Thomas A Rasmussen, Anthony D Kelleher, Deborah Cromer, Miles P Davenport
Published 2016-08-01

Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission.

by Mykola Pinkevych, Deborah Cromer, Martin Tolstrup, Andrew J Grimm, David A Cooper, Sharon R Lewin, Ole S Søgaard, Thomas A Rasmussen, Stephen J Kent, Anthony D Kelleher, Miles P Davenport
Published 2016-08-01

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.

by Mykola Pinkevych, Deborah Cromer, Martin Tolstrup, Andrew J Grimm, David A Cooper, Sharon R Lewin, Ole S Søgaard, Thomas A Rasmussen, Stephen J Kent, Anthony D Kelleher, Miles P Davenport
Published 2015-07-01

Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients

by Ane Bjerg Christensen, Anders Dige, Johan Vad-Nielsen, Christel R. Brinkmann, Mia Bendix, Lars Østergaard, Martin Tolstrup, Ole S. Søgaard, Thomas A. Rasmussen, Jens Randel Nyengaard, Jørgen Agnholt, Paul W. Denton
Published 2015-01-01

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-I...

by Christel Rothe Brinkmann, Jesper Falkesgaard Højen, Thomas Aagaard Rasmussen, Anne Sofie Kjær, Rikke Olesen, Paul W. Denton, Lars Østergaard, Zhengyu Ouyang, Mathias Lichterfeld, Xu Yu, Ole Schmeltz Søgaard, Charles Dinarello, Martin Tolstrup, Ana Fernandez-Sesma
Published 2018-02-01

SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity

by Stine SF Nielsen, Line K Vibholm, Ida Monrad, Rikke Olesen, Giacomo S Frattari, Marie H Pahus, Jesper F Højen, Jesper D Gunst, Christian Erikstrup, Andreas Holleufer, Rune Hartmann, Lars Østergaard, Ole S Søgaard, Mariane H Schleimann, Martin Tolstrup
Published 2021-06-01